The animal health division of Merck & Co Inc has reached an agreement to acquire a controlling interest in Vallée SA , a privately-held producer of animal health products in Brazil. Vallée has a portfolio of more than 100 products including anti-infectives and vaccines.
As gene editing technologies gain more traction, companies producing the new technologies are attracting more money from investors. One such company is CRISPR Therapeutics of Switzerland that has a number of preclinical projects investigating gene editing for therapeutic use.
Merck & Co Inc has announced plans to acquire privately-held Afferent Pharmaceuticals of San Mateo, California, US for up to $1.25 billion depending on the achievement of specific clinical and commercial milestones.
Jazz Pharmaceuticals Plc, a Dublin-based, Nasdaq-listed company that has built a diversified pharmaceutical business through acquisitions, has made an offer to acquire Celator Pharmaceuticals Inc and its late-stage product for treating acute myeloid leukaemia (AML) for about $1.5 billion.
A UK-based gene therapy company, Freeline Therapeutics, has received a third investment from the UCL Technology Fund, which supports research from University College London. The fund is managed by Albion Ventures in collaboration with UCL Business, the university’s technology transfer office.
Pfizer Inc has completed its $5.2 billion acquisition of Anacor Pharmaceuticals Inc, a US company that is developing small molecule therapeutics using an element in nature called boron. Boron is ingested through the consumption of fruits, vegetables, milk and coffee.
Italy-based MolMed SpA has become the seventh company to get a positive recommendation from the European regulator to market an advanced therapy medicinal product, a group that includes cell and gene therapies as well as tissue-engineered products.
As gene editing technologies gain traction in laboratories around the world, companies producing the new technologies are attracting more money from investors. An example is CRISPR Therapeutics which has a number of preclinical projects where it is investigating gene editing for therapeutic use.
Verona Pharmaceuticals Plc, which is developing products for respiratory diseases, has made arrangements to raise £44.7 million with an equity placement sweetened with warrants. The proceeds will be used for a Phase 2b trial of its lead product RPL554 for chronic obstructive pulmonary disease.
The share price of Circassia Pharmaceuticals Plc fell by 64.85% to 95 pence in mid-morning trading on 20 June following the announcement that its phase-3 trial of its cat allergy drug failed to meet its primary endpoint.